NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

RegulatoryapprovedNEREUSPositive

AI Analysis

Summary

Vanda Pharmaceuticals announced that NEREUS (tradipitant), its FDA-approved prescription medication for motion sickness prevention, will sponsor an IndyCar entry as a marketing initiative. This marks the first new motion sickness treatment approved in 47 years.

Outcome Details

First new prescription medication approved for prevention of motion sickness in 47 years

Importance:3/10

Sentiment:

0.70

FDA approvalmotion sicknessfirst-in-classmarketing

Related Companies

$VNDA

Read the original article

Published by PR Newswire Pharma on July 15, 2026 8:30 PM

Read Original